Philips Launches Azurion with FlexArm to Set New Standard for the Future of Image-Guided Procedures

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Azurion with FlexArm, to set a new standard for patient imaging and positioning flexibility for image-guided procedures.

During increasingly complex interventions, clinicians need to quickly and easily visualize critical anatomy and identify changes to the patient during the procedure. Azurion with FlexArm includes a set of innovations that makes it easier for the clinician to perform imaging across the whole patient in both 2D and 3D. As the clinician moves the system, the image beam automatically maintains alignment with the patient, allowing more consistent visualization and enabling them to keep their focus on the treatment.

"With FlexArm, Philips' engineers have overcome near-impossible geometric and mechanical barriers to enable clinicians to achieve clinical excellence in image-guided therapy," said Barry T. Katzen, MD, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, Baptist Health South Florida (U.S.). "FlexArm enables us to dramatically optimize procedures around the patient: we can get the optimal view of what's going on inside the patient without encumbering all of the clinicians that are working around the table. The result is an innovation that’s not only clinically important but also very simple and intuitive to use - a critical factor in the heat of a complex procedure."

The range and complexity of diseases that can be treated with minimally invasive procedures continues to expand. Correspondingly, the procedures themselves are also becoming more complex, requiring more physicians from different disciplines to be at the patient’s tableside, working together in a highly coordinated way. As a result, the clinical team is required to carry out increasingly challenging procedures in a highly constrained environment.

Azurion with FlexArm's innovative design provides exceptional flexibility and intuitive control. Powered by a unique smart kinematic engine, the system moves on eight different axes, all controlled with its single 'Axsys' controller. Simulation tests with clinicians have demonstrated the system's potential to significantly reduce the repositioning of the patient, staff and equipment to improve access for minimally invasive procedures, including those that enter the body through the patient's wrist ('radial access'), and to reduce the risk of unintentional pulling of wires and tubes, as well as significant time savings [1]. The system is ideally suited for Hybrid ORs that cater to multiple specialties in one room, such as a combination of surgical and endovascular procedures.

"Two years on from its launch, Azurion is now established as our leading platform for interventional procedures, favored by clinicians for its intuitive, seamless approach that enables them to focus on treating the patient, and by hospital administrators for its positive impact on productivity and efficiency," said Ronald Tabaksblat, Business Leader Image Guided Therapy Systems, Philips. "FlexArm is the natural next step in our Azurion innovation journey, combining clinical and operational benefits to improve patient care and reduce costs, while opening up opportunities for new image-guided procedures as the field continues grow."

Azurion with FlexArm is the latest innovation in Philips' unique portfolio of systems, smart devices, software and services in image-guided therapy, which combine to provide healthcare providers with sophisticated, procedure-oriented solutions. As the range of diseases that can be treated with minimally invasive procedures continues to expand and the procedures themselves become more efficient, the patient's treatment experience continues to improve. They experience less trauma, and as a result their stay in hospital can be dramatically reduced - often returning home after one night in hospital, and for some procedures even leaving the hospital on the same day.

Since its global launch in February 2017, over 450.000 patients have been treated in more than 80 countries using a Philips Azurion system. The Philips Azurion 7 C20 with FlexArm is CE marked and has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2017 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries.

1. Uselab simulation test with 15 clinicians.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...